201 related articles for article (PubMed ID: 36635380)
1. Control of acute myeloid leukemia by a trifunctional NKp46-CD16a-NK cell engager targeting CD123.
Gauthier L; Virone-Oddos A; Beninga J; Rossi B; Nicolazzi C; Amara C; Blanchard-Alvarez A; Gourdin N; Courta J; Basset A; Agnel M; Guillot F; Grondin G; Bonnevaux H; Bauchet AL; Morel A; Morel Y; Chiron M; Vivier E
Nat Biotechnol; 2023 Sep; 41(9):1296-1306. PubMed ID: 36635380
[TBL] [Abstract][Full Text] [Related]
2. Developing a mechanistic translational PK/PD model for a trifunctional NK cell engager to predict the first-in-human dose for acute myeloid leukemia.
Choi SL; Valente D; Virone-Oddos A; Mauriac C
Clin Transl Sci; 2024 Jan; 17(1):e13689. PubMed ID: 37990450
[TBL] [Abstract][Full Text] [Related]
3. A Trifunctional Natural Killer Cell Engager Can Target CD123+ Leukemia.
Cancer Discov; 2023 Mar; 13(3):527. PubMed ID: 36661385
[TBL] [Abstract][Full Text] [Related]
4. Targeting of acute myeloid leukemia in vitro and in vivo with an anti-CD123 mAb engineered for optimal ADCC.
Busfield SJ; Biondo M; Wong M; Ramshaw HS; Lee EM; Ghosh S; Braley H; Panousis C; Roberts AW; He SZ; Thomas D; Fabri L; Vairo G; Lock RB; Lopez AF; Nash AD
Leukemia; 2014 Nov; 28(11):2213-21. PubMed ID: 24705479
[TBL] [Abstract][Full Text] [Related]
5. Dual-targeting CD33/CD123 NANOBODY T-cell engager with potent anti-AML activity and good safety profile.
Zeng Z; Roobrouck A; Deschamps G; Bonnevaux H; Guerif S; De Brabandere V; Amara C; Dejonckheere E; Virone-Oddos A; Chiron M; Konopleva M; Dullaers M
Blood Adv; 2024 May; 8(9):2059-2073. PubMed ID: 38266153
[TBL] [Abstract][Full Text] [Related]
6. CD16
Williams BA; Wang XH; Leyton JV; Maghera S; Deif B; Reilly RM; Minden MD; Keating A
Haematologica; 2018 Oct; 103(10):1720-1729. PubMed ID: 29976748
[TBL] [Abstract][Full Text] [Related]
7. Development of a novel fully-human anti-CD123 antibody to target acute myeloid leukemia.
Hutmacher C; Volta L; Rinaldi F; Murer P; Myburgh R; Manz MG; Neri D
Leuk Res; 2019 Sep; 84():106178. PubMed ID: 31326578
[TBL] [Abstract][Full Text] [Related]
8. Improved Activity against Acute Myeloid Leukemia with Chimeric Antigen Receptor (CAR)-NK-92 Cells Designed to Target CD123.
Morgan MA; Kloos A; Lenz D; Kattre N; Nowak J; Bentele M; Keisker M; Dahlke J; Zimmermann K; Sauer M; Heuser M; Schambach A
Viruses; 2021 Jul; 13(7):. PubMed ID: 34372571
[TBL] [Abstract][Full Text] [Related]
9. Safe and effective off-the-shelf immunotherapy based on CAR.CD123-NK cells for the treatment of acute myeloid leukaemia.
Caruso S; De Angelis B; Del Bufalo F; Ciccone R; Donsante S; Volpe G; Manni S; Guercio M; Pezzella M; Iaffaldano L; Silvestris DA; Sinibaldi M; Di Cecca S; Pitisci A; Velardi E; Merli P; Algeri M; Lodi M; Paganelli V; Serafini M; Riminucci M; Locatelli F; Quintarelli C
J Hematol Oncol; 2022 Nov; 15(1):163. PubMed ID: 36335396
[TBL] [Abstract][Full Text] [Related]
10. Pre-clinical development of a novel CD3-CD123 bispecific T-cell engager using cross-over dual-variable domain (CODV) format for acute myeloid leukemia (AML) treatment.
Bonnevaux H; Guerif S; Albrecht J; Jouannot E; De Gallier T; Beil C; Lange C; Leuschner WD; Schneider M; Lemoine C; Caron A; Amara C; Barrière C; Siavellis J; Bardet V; Luna E; Agrawal P; Drake DR; Rao E; Wonerow P; Carrez C; Blanc V; Hsu K; Wiederschain D; Fraenkel PG; Virone-Oddos A
Oncoimmunology; 2021; 10(1):1945803. PubMed ID: 34484869
[TBL] [Abstract][Full Text] [Related]
11. CD123 target validation and preclinical evaluation of ADCC activity of anti-CD123 antibody CSL362 in combination with NKs from AML patients in remission.
Xie LH; Biondo M; Busfield SJ; Arruda A; Yang X; Vairo G; Minden MD
Blood Cancer J; 2017 Jun; 7(6):e567. PubMed ID: 28574487
[TBL] [Abstract][Full Text] [Related]
12. CD123-Engager T Cells as a Novel Immunotherapeutic for Acute Myeloid Leukemia.
Bonifant CL; Szoor A; Torres D; Joseph N; Velasquez MP; Iwahori K; Gaikwad A; Nguyen P; Arber C; Song XT; Redell M; Gottschalk S
Mol Ther; 2016 Sep; 24(9):1615-26. PubMed ID: 27401038
[TBL] [Abstract][Full Text] [Related]
13. Optimization of Human NK Cell Manufacturing: Fully Automated Separation, Improved Ex Vivo Expansion Using IL-21 with Autologous Feeder Cells, and Generation of Anti-CD123-CAR-Expressing Effector Cells.
Klöß S; Oberschmidt O; Morgan M; Dahlke J; Arseniev L; Huppert V; Granzin M; Gardlowski T; Matthies N; Soltenborn S; Schambach A; Koehl U
Hum Gene Ther; 2017 Oct; 28(10):897-913. PubMed ID: 28810809
[TBL] [Abstract][Full Text] [Related]
14. T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia.
Mardiros A; Dos Santos C; McDonald T; Brown CE; Wang X; Budde LE; Hoffman L; Aguilar B; Chang WC; Bretzlaff W; Chang B; Jonnalagadda M; Starr R; Ostberg JR; Jensen MC; Bhatia R; Forman SJ
Blood; 2013 Oct; 122(18):3138-48. PubMed ID: 24030378
[TBL] [Abstract][Full Text] [Related]
15. Targeting CD123 in acute myeloid leukemia using a T-cell-directed dual-affinity retargeting platform.
Al-Hussaini M; Rettig MP; Ritchey JK; Karpova D; Uy GL; Eissenberg LG; Gao F; Eades WC; Bonvini E; Chichili GR; Moore PA; Johnson S; Collins L; DiPersio JF
Blood; 2016 Jan; 127(1):122-31. PubMed ID: 26531164
[TBL] [Abstract][Full Text] [Related]
16. Improving the anti-acute myeloid leukemia activity of CD123-specific engager T cells by MyD88 and CD40 costimulation.
Vaidya A; Doherty E; Wu X; Huang S; Hebbar N; Thanekar U; Bonifant CL; Cheng C; Gottschalk S; Velasquez MP
Haematologica; 2023 Apr; 108(4):1039-1052. PubMed ID: 35899386
[TBL] [Abstract][Full Text] [Related]
17. Valproic acid increases CAR T cell cytotoxicity against acute myeloid leukemia.
Wen J; Chen Y; Yang J; Dai C; Yu S; Zhong W; Liu L; He C; Zhang W; Yang T; Liu L; Hu J
J Immunother Cancer; 2023 Jul; 11(7):. PubMed ID: 37524506
[TBL] [Abstract][Full Text] [Related]
18. [Construction of a new anti-CD123 chimeric antigen receptor T cells and effect of anti-acute myeloid leukemia].
Wang ZZ; Lu Y; Xu YX; Xing HY; Tang KJ; Tian Z; Rao Q; Wang M; Xiong DS; Wang JX
Zhonghua Xue Ye Xue Za Zhi; 2020 Mar; 41(3):192-197. PubMed ID: 32311887
[No Abstract] [Full Text] [Related]
19. Examination of IgG Fc Receptor CD16A and CD64 Expression by Canine Leukocytes and Their ADCC Activity in Engineered NK Cells.
Hullsiek R; Li Y; Snyder KM; Wang S; Di D; Borgatti A; Lee C; Moore PF; Zhu C; Fattori C; Modiano JF; Wu J; Walcheck B
Front Immunol; 2022; 13():841859. PubMed ID: 35281028
[TBL] [Abstract][Full Text] [Related]
20. Humanized anti-CD123 antibody facilitates NK cell antibody-dependent cell-mediated cytotoxicity (ADCC) of Hodgkin lymphoma targets via ARF6/PLD-1.
Ernst D; Williams BA; Wang XH; Yoon N; Kim KP; Chiu J; Luo ZJ; Hermans KG; Krueger J; Keating A
Blood Cancer J; 2019 Jan; 9(2):6. PubMed ID: 30647406
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
